Navigation Links
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
Date:3/3/2010

Toronto Stock Exchange Symbol: MS

EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxin(TM), a therapeutic hemoperfusion device for the treatment of severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxin(TM) in the United States.

Spectral also reported that it has closed its previously announced private placement of 48,750,000 units of the Company for gross proceeds of $19.5 million'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
2. BioMS Medical provides corporate update
3. BioMS Medical Announces Third Quarter 2009 Results
4. BioMS Medical announces second quarter 2009 results
5. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
6. BioMS Medical to participate in panel session at Bio International Convention 2009
7. BioMS Medical Announces First quarter 2009 results
8. BioMS Medical to present at Alberta Economic Forum in Geneva
9. BioMS Medical to present at BioFinance 2009
10. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
11. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/7264hm/biomarkers ) has ... "Biomarkers - Technologies, Markets and Companies" ... the broad definition of a biomarker as a ... as an indicator of normal biological or pathogenic ... therapeutic intervention. Tests based on biomarkers have been ...
(Date:6/2/2015)... MALVERN, Pa. , June 2, 2015 /PRNewswire/ ... will be attending the BIO Exhibition 2015 in ... BIO Exhibition, the world,s largest biotechnology gathering, allows ... to high-level executives, where they can evaluate emerging ... has significant eClinical expertise in the design, implementation ...
(Date:6/2/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in ... that Dr. Pamela Pavco , RXi,s ... 23 rd World Congress of Dermatology ... in-depth presentations by world-class clinicians and/or investigators, ...
(Date:6/2/2015)... , June 2, 2015 ... the global antibiotic resistance problem  MGB ... class of anti-infectives, to address the major global ... has developed a stable intravenous (IV) formulation of MGB-BP-3, ... resistant Gram-positive hospital-acquired infections.  The intravenous formulation ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3
... International Market Opportunities for the Company,s Medical ... ... PIP ), a biodefense company developing medical countermeasures,against biological and chemical ... a special UK government advisor., Lord Moonie will assist PharmAthene ...
... --,China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ... in the People,s,Republic of China ("PRC"), today announced ... a.m. EDT on Friday, August 15, 2008, to ... in the live conference call, please dial the ...
... Duff & Phelps Corporation,(NYSE: DUF ), a ... announced that it has acquired the Lumin Expert ... specializes in,intellectual property dispute support and expert testimony. ... Lumin performs independent analyses of financial, economic and ...
Cached Biology Technology:Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene 2Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene 3China Biologic Products Announces Second Quarter 2008 Results Conference Call 2Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice 2
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Northwest National Laboratory scientists have used electrostatic attraction ... carbon nanotubes. , This configuration can accommodate ... monitoring to infectious-agent detection, said Yuehe Lin, who ... campus' W.R. Wiley Environmental Molecular Sciences Laboratory. ...
... a vaccine designed to fight avian influenza will begin this ... is part of a multicenter trial that will test a ... whether the vaccine still triggers a strong immune response at ... the National Institute of Allergy and Infectious Diseases of the ...
... online today in the journal Nature Methods, researchers at ... powerful new tool that will facilitate genetic research and ... genetic disease. , The researchers have combined several ... lentiviral vector ?a gene delivery system partly derived from ...
Cached Biology News:A biosensor layered like lasagna 2Duke to test bird flu vaccine dosing 2Swiss researchers develop all-in-one remote control gene expression tool 2
... Rabbit polyclonal to BMP2 BMP2 ... beta (TGFB) superfamily. Bone morphogenic protein ... candidate gene for the autosomal dominant ... Immunogen: Synthetic peptide: ...
... foil heat sealing material is suitable ... a screw down heated lid), especially ... useful method for sample retrieval. Multiple ... existing seal. Ideal for compound management ...
...
...
Biology Products: